Utibron Neohaler Available for Maintenance Treatment of COPD

This article originally appeared here.
Share this content:
The Utibron Neohaler was initially approved by the FDA in October 2015.
The Utibron Neohaler was initially approved by the FDA in October 2015.

Sunovion announced the availability of Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Sunovion has taken over US commercialization rights from Novartis for Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler. Utibron Neohaler combines indacaterol, a long-acting beta agonist (LABA), and glycopyrrolate, a long-acting muscarinic antagonist (LAMA). It was initially approved by the FDA in October 2015. 

Utibron Neohaler is available as 27.5mcg/15.6mcg strength capsules containing dry powder for oral inhalation with the Neohaler device. Seebri Neohaler and Arcapta Neohaler will be launched under Sunovion between April 2017 and March 2018.

Reference

  1. Important safety information and indication for Utibron Neohaler. Utibron Neohaler. Accessed April 13, 2017.

Sign Up for Free e-newsletters